Equity Medical, LLC | Bowling Green, KY

Research site

(Unclaimed)

Location

610 Cave Mill Rd, Bowling Green, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Ruxolitinib

Rocatinlimab

Ustekinumab

CDX-0159

Remibrutinib

Litifilimab

ESK-001

Amlitelimab

Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 14 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: Litifilimab

Drug: Placebo

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo 1

Drug: Placebo 2

Locations recently updated

A Study of Barzolvolimab in Patients With Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Enrolling

Atopic Dermatitis

Biological: Barzolvolimab

Drug: Matching placebo

A Study of Barzolvolimab in Patients With Prurigo Nodularis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling

Prurigo Nodularis

Other: Matching Placebo

Biological: barzolvolimab

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib

Drug: Dupilumab

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid)

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo

Drug: Lutikizumab

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting

Plaque Psoriasis

Drug: Ustekinumab

Drug: Matching Placebo to Ustekinumab

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

Drug: Placebo

Locations recently updated

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis (ONWARD3)

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling

Psoriasis

Severe Psoriasis

Drug: Open-Label ESK-001

Drug: Blinded ESK-001

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Enrolling

Hidradenitis Suppurativa

Drug: Ruxolitinib Cream

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Enrolling

Hidradenitis Suppurativa (HS)

Biological: Tibulizumab Dose B

Other: Placebo